AMAR - Amarillo Biosciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2311
-0.0285 (-10.96%)
At close: 9:30AM EDT
Stock chart is not supported by your current browser
Previous Close0.2596
Open0.2311
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2311 - 0.2311
52 Week Range0.1840 - 0.4700
Volume978
Avg. Volume4,791
Market Cap9.294M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.0430
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.90
  • Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications
    GlobeNewswire

    Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications

    Amarillo, TX, Feb. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China licensing partner, Xiamen Weiyang Pharmaceutical Co., Ltd. (“Xiamen Weiyang”), has begun initiating the sharing of proprietary clinical research information with health officials in China to potentially explore the effect of ABI’s low-dose oral interferon in combating the spread of novel coronavirus, now officially known as Covid-19, along with other related viral indications such as influenza. There are currently no approved therapeutics or vaccines for Covid-19.

  • Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement
    GlobeNewswire

    Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement

    Amarillo, TX, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that it has entered into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical Co., Ltd., a company organized under the laws of the People’s Republic of China (“Xiamen Weiyang”), setting forth the proposed terms for a cooperative development and licensing venture in China.  The consummation of the proposed transaction is contingent on a mutually agreeable definitive agreement. Dr. Stephen T. Chen, ABI’s CEO, stated, “We are pleased to announce this proposed venture with Xiamen Weiyang.